Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial

JAMA

Volumn 284, Issue 10, 2000, Pages 1263-1270

  Elam, Marshall B ^a   Hunninghake, Donald B ^b   Davis, Kathryn B ^c,d   Garg, Rekha ^e,i   Johnson, Craig ^d   Egan, Debra ^e   Kostis, John B ^f   Sheps, David S ^g,j   Brinton, Eliot A ^h,k  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Axio Research Corporation   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ Eli Lilly Co

^j UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034644442     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.10.1263     Document Type: Article

References (32)

1. Influence of nicotinic acid on serum cholesterol in man
2. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
3. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus
4. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: A prospective trial
5. Clofibrate and niacin in coronary heart disease
6. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
7. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipo-protein B.
8. Beneficial effects of combined colestipol-niacin therapy on coronary athero-sclerosis and coronary venous bypass grafts
9. Predisposition to atherosclerosis of the head, heart and legs: The Framingham Study
10. Lipid-lowering therapy and macrovascular disease in diabetes mellitus
11. Dyslipidemias in patients with diabetes mellitus: Classification and risks and benefits of therapy
12. American Diabetes Association. Management of dyslipidemia in adults with diabetes
13. Management of dyslipidemia in adults with diabetes
14. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study
15. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
16. Summary of the Second Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
17. The effect of nicotinic acid in diabetes mellitus
18. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance
19. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid
20. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid
21. Studies of nicotinic acid use in hypercholesterolemia
22. The effect of large doses of nicotinic acid on circulation, lipids and carbohydrate tolerance
23. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans
24. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia: Effects on serum lipids, lipoproteins, glucose tolerance and tolerability
25. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders
26. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
27. Niacin decreases removal of high-density lipoprotein apolipo-protein A-I but not cholesterol ester by Hep G2 cells: Implication for reverse cholesterol transport
28. Drug treatment of lipid disorders
29. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM [published erratum appears in Diabetes 1990;39:1313]
30. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis Of the Scandinavian Simvastatin Survival Study (4S)
31. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
32. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol